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Key Points
• FcgRIIA activation is key
for platelet aggregation in
response to bacteria, and
depends on IgG and aIIbb3
engagement.
• PF4 binds to bacteria and
reduces the lag time for
platelet aggregation.
Bacterial adhesion to platelets is mediated via a range of strain-specific bacterial
surface proteins that bind to a variety of platelet receptors. It is unclear how these
interactions lead to platelet activation. We demonstrate a critical role for the immune
receptor FcgRIIA, aIIbb3, and Src and Syk tyrosine kinases in platelet activation by
Staphylococcus aureus, Streptococcus sanguinis, Streptococcus gordonii, Strepto-
coccus oralis, and Streptococcus pneumoniae. FcgRIIA activation is dependent on
immunoglobulin G (IgG) and aIIbb3 engagement. Moreover, feedback agonists
adenosine 59-diphosphate and thromboxane A2 aremandatory for platelet aggregation.
Additionally, platelet factor 4 (PF4) binds to bacteria and reduces the lag time for
aggregation, andgrayplatelet syndromea-granule–deficient plateletsdonot aggregate
to 4 of 5 bacterial strains. We propose that FcgRIIA-mediated activation is a common
response mechanism used against a wide range of bacteria, and that release of
secondary mediators and PF4 serve as a positive feedback mechanism for activation through an IgG-dependent pathway. (Blood.
2014;123(20):3166-3174)
Introduction
Despite an increasingly recognized role for platelets in immunity,1-4
our knowledge of the molecular events that control platelet-bacteria
interactions is rudimentary. Moreover, there is increasing evidence
that acute and chronic infections play a role in the development and
progression of cardiovascular and related diseases including in-
fective endocarditis, atherothrombosis, and sepsis,5-9 and that this
may involve direct activation of platelets by bacteria. Platelet
activation can be responsible for themost severe sequelae of bacterial
infection. For example, infective endocarditis is a focal infection of
the heart valves characterized by inflammation that is associatedwith
the build-up of platelets, fibrin, and bacteria on the valves of the
heart.10 The biggest risk for patients is embolization of the clots to the
brain, causingmultiple small infarcts. Another life-threatening disease
is sepsis, which can lead to sepsis-associated disseminated coagulop-
athy during which clotting factors are consumed by disseminated
microvascular thrombosis. The bacterial species that are more fre-
quently involved in these conditions include viridans group strepto-
cocci (Streptococcus sanguinis, Streptococcus gordonii, and
Streptococcus oralis) and Staphylococcus aureus11,12 in infective
endocarditis or Streptococcus pneumoniae in sepsis. Strains of
these species have been shown to stimulate platelet aggregation
and secretion directly.13-17
Bacteria can interact with platelets through a variety of mech-
anisms.4 Bacteria express proteins that recognize platelet receptors.
For example, oral streptococci express a family of highly glyco-
sylated serine-rich proteins that bind to platelet glycoprotein Iba
(GPIba): S sanguinis (expresses serine-rich protein A),16 S gordonii
(hemagglutinin salivary antigen),17 and S oralis (whose GPIba
ligand has yet to be identified15). In addition, S gordonii expresses
platelet adherence protein A18 and S aureus expresses iron-
regulated surface determinant,19 both of which bind to platelet
integrin aIIbb3 (GPIIb/IIIa). S pneumoniae binds to platelet Toll-
like receptor 2 through an unidentified ligand. Bacteria also interact
with plasma proteins that bind platelet receptors. For example,
S aureus expresses cell wall proteins, clumping factors A andB (ClfA
and ClfB) and fibronectin-binding proteinA,which bind to fibrinogen
and immunoglobulin G (IgG) leading to cross-linking of aIIbb3
and FcgRIIA, respectively.4 Similarly, S aureus protein A can
bridge vonWillebrand factor toaIIbb3.4,14 Additionally, secretion
of prothrombin-activating molecules, staphylocoagulase and von
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Willebrand factor–binding protein, by S aureus promotes the
formation of fibrin scaffolds that facilitate bacteria-platelet inter-
actions.20 Furthermore, bacteria can secrete toxins that activate
platelet receptors. For example, Porphyromonas gingivalis secretes
the protease gingipain, which activates protease-activated receptor
121 and S aureus releases a-toxin that causes platelet secretion.4
Bacteria-induced platelet aggregation, as measured by Born
aggregometry, is associated with a characteristic lag time that varies
from seconds to several minutes and is then followed by full aggre-
gation. In contrast, most platelet agonists cause rapid activation,
which can give rise to partial aggregationwhen low concentrations of
agonist are used. This suggests that bacteria have a unique positive
feedback mechanism that gives rise to an “all-or-nothing” response.
FcgRIIA has been shown to play a role in mediating activation
to several strains of bacteria.4,15 FcgRIIA is a low-affinity receptor
for the Fc region of IgGs and is activated by immune complexes
and other IgG-coated targets. FcgRIIA signals through Src and
Syk tyrosine kinases via a dual YxxL sequence known as an
immunoreceptor tyrosine-based activation motif that is present in
its cytoplasmic tail.22 Pathologically, FcgRIIA plays a critical
role in heparin-induced thrombocytopenia (HIT), a potentially
life-threatening disorder in which antibodies against platelet
factor 4 (PF4)/heparin complexes induce platelet activation.23,24
It has recently been proposed that the natural targets for the HIT
antibodies are PF4-coated bacteria, and that antibody recognition
mediates bacterial clearance by polymorphonuclear leukocytes.25,26
FcgRIIA also functions as an adaptor protein for the major platelet
integrin aIIbb3 mediating signaling independent of extracellular
engagement.27,28 Following activation by platelet agonists, aIIbb3
shifts from its low affinity to a high-affinity state (“inside-out”
signaling). Ligand-occupied aIIbb3 in turn reinforces activation
via “outside-in” signaling, which is mediated in part through
FcgRIIA.27,28 Activated aIIbb3 also mediates platelet aggregation
by its ability to bind soluble fibrinogen, which bridges neighboring
platelets.29
In the present study, we have investigated the hypothesis that
bacterial activation of platelets is mediated through a common
pathway that is dependent on FcgRIIA and that this pathway is
reinforced during platelet activation possibly through secretion of
PF4 and other secondary mediators.
Methods
Reagents
Fibrinogen was from Calbiochem (Merck Millipore). When indicated,
fibrinogen was depleted of IgGs by incubation with protein A (rec-Protein
A-Sepharose 4B Conjugate; Life Technologies). Pooled human IgGs
(hIgGs) from healthy donors and unfractionated heparin (UFH) were from
Sigma-Aldrich. Purified human PF4 was from ChromaTec. Anti-FcgRIIA
monoclonal antibody (mAb) IV.3 was purified in the laboratory from
a hybridoma. Anti-mouse IgG F(ab9)2 was from Life Technologies. Rabbit
anti-human PLCg2 polyclonal antibody (pAb) sc-407 was from Santa Cruz
Biotechnology. Goat anti-human BAF1330 (CD32/FcgRIIB Ab) was from
R&D Systems. FcgRIIB is absent in human platelets and, therefore, this
antibody can be used for the detection of FcgRIIA.30 Other reagents were
from described sources or Sigma-Aldrich.31-34
Bacterial culture and preparation
Bacteria were gifts from Prof Mark Herzberg (University of Minnesota;
S sanguinis 133-79), Prof Timothy Foster (Trinity College Dublin; S aureus
Newman), Prof Howard Jenkinson (University of Bristol; S gordonii DL1,
S pneumoniae IO1196), and Prof Ian Douglas (University of Sheffield;
S oralis CR834).
All strains were cultured anaerobically at 37°C overnight and prepared as
described.13,15Washed bacteriawere adjusted in phosphate-buffered saline to
an optical density of 1.6 at a wavelength of 600 nm corresponding to the
following concentrations: S sanguinis 133-79, 6 3 108 CFU/mL; S aureus
Newman, 1 3 109 CFU/mL; S gordonii DL1, 3 3 109 CFU/mL; S oralis
CR834, 43 109CFU/mL; S pneumoniae IO1196, 73 108 CFU/mL.Bacteria
were used at a 10-fold dilution in aggregation assays.
Human platelets
Bloodwas drawn in sodiumcitrate (for platelet-rich plasma [PRP]) orACD-A
(forwashed platelets) fromhealthy volunteerswho had not taken nonsteroidal
anti-inflammatory medication in the previous 10 days. PRP15 and washed
platelets35 were obtained as published. The study design was approved by the
relevant ethics committees (Birmingham: ERN_11-0175; Dublin: REC679b).
The gray platelet syndrome (GPS) patientwas recruited to theUnitedKingdom
Genotyping and Phenotyping of Platelets (UK GAPP) study (ISRCTN
77951167). Due to the slight increase in size of the platelets, PRP from the
patient and a paired control was prepared at a reduced level of centrifugation
(10 minutes at 100g). Approval was obtained from the institutional review
board (number ERN_12-0799) for these studies. Informed consent was
provided according to the Declaration of Helsinki.
Mouse platelets
Mice transgenic for human FcgRIIA were obtained from The Jackson Lab-
oratory andbred as heterozygotes. ControlswereFcgRIIA-negative littermates.
Blood was obtained as previously described.36 N-2-hydroxyethylpiperazine-
N9-2-ethanesulfonic acid–Tyrode buffer36 was added to the blood at a ratio of
1:5 and PRP was obtained by centrifugation at 200g for 6 minutes. The
recovered PRP was diluted in buffer (up to 50% dilution) to give a platelet
concentration of$23 108 platelets/mL. All experiments were performed in
accordance with UK laws with approval of local ethics committees and under
Animal (Scientific Procedures) Act 1986 regulated licenses.
Aggregation and ATP secretion
Platelet aggregation was assessed by light transmission in a PAP-4 aggre-
gometer for up to 30 minutes. Time-matched controls were run alongside.
Stimulation by cross-linking of FcgRIIA was performed by preincubation
of platelets for 3minutes withmAb IV.3 (4mg/mL) followed by anti-mouse
IgG F(ab9)2 (30 mg/mL). Adenosine triphosphate (ATP) release was
assessed at the end of the recording using a luciferin-luciferase–based
assay.13
PF4 secretion
Aggregation reactions were stopped at the end of the experiment by
addition of prostacyclin (4mM) and centrifuged at 1500g for 10minutes at
room temperature. Plasma supernatants were obtained for PF4 measure-
ment by enzyme-linked immunosorbent assay (ELISA) (Human CXCL4/
PF4 ELISA; R&D Systems).
Protein phosphorylation
Aggregation reactions were stopped by addition of an equal volume of ice-
cold phosphate-buffered saline and platelets were pelleted by centrifugation
at 8500g for 30 seconds at 4°C. Platelets were lysed with ice-cold 13 lysis
buffer plus inhibitors.31 Immunoprecipitations (IPs) and protein detection
were conducted as previously described31 but without a preclearing step for
FcgRIIA and Syk IPs (to preserve FcgRIIA). mAb IV.3 (mouse anti-human
FcgRIIA), BR15 (rabbit anti-Syk pAb), and rabbit anti-human PLCg2 pAb
were used for IP. Samples were blotted for phosphotyrosine usingmAb 4G10
and reprobed with biotinylated BAF1330 antibody for FcgRIIA and with the
same IP antibodies for Syk and PLCg2 followed by addition of anti-rabbit
horseradish peroxidase.
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PF4 binding to bacteria
PF4 binding to bacteria was measured using biotinylated human PF4
(20 mg/mL) as previously described.25 Where indicated, bacteria-PF4
incubations were performed in the presence of 46% pooled plasma from
healthy donors.
Statistical analysis
Statistical analysis was performed using GraphPad (Prism). Data are
presented as the mean 6 SD unless otherwise stated, and comparisons
between mean values were performed using the Student t test, or analysis of
variance when multiple samples were compared. P , .05 (2-tailed) was
considered significant.
Results
Bacteria stimulate platelet aggregation and secretion via
FcgRIIA and aIIbb3
The strains of the 5 bacterial species used in this study are known to
induce “all-or-nothing” aggregation of platelets following a lag time
that decreases with increasing concentrations of bacteria, as illus-
trated for 2 of them in supplemental Figure 1A-B (available on the
BloodWeb site). This is in contrast to the immediate onset and partial
response induced by cross-linking of an intermediate concentration
ofmAb IV.3 to induce clustering of FcgRIIA,37with full aggregation
observed in response to a higher concentration (supplemental
Figure 1C).
In this study, bacteria were used at concentrations that have been
optimized previously. All strains stimulated maximal platelet aggre-
gation but with a strain-specific delay that varied from 120 to 900
seconds (Figure 1A). In all cases, aggregation was associated with
robust secretion of dense anda-granules as shown bymeasurement
of ATP and PF4, respectively, which is similar in magnitude to that
induced by FcgRIIA clustering (Figure 1B-C). Consistent with
previous studies,13-17 aggregation was blocked to all stimuli in the
presence of the aIIbb3 antagonist Integrilin (eptifibatide) (supple-
mental Figure 2A). Unexpectedly, however, dense and a-granule
secretion was also inhibited by Integrilin demonstrating that secretion
is dependent on aIIbb3 engagement (Figure 1B-C). In contrast,
secretion induced by cross-linked mAb IV.3 was not altered in the
presence of Integrilin (Figure 1B-C).
Several studies have reported a critical role for IgG and FcgRIIA in
platelet activationby several of thebacteria used in this study.13,15,16,38,39
In line with this, we demonstrate that mAb IV.3 blocks aggregation
(Figure 2A; supplemental Figure 2B) and both dense and a-granule
secretion (Figure 2B, andnot shown) to the 5 strains,whereas it hadno
effect on thrombin receptor-activating peptide (TRAP)-induced ac-
tivation. As FcgRIIA signals through Src and Syk tyrosine kinases,
and consistent with a role for FcgRIIA, inhibitors of Src (dasatinib)
or Syk (PRT-060318) also abrogated aggregation to all 5 strains
(Figure 2C-D; supplemental Figure 2C-D).
Bacteria-induced tyrosine phosphorylation of FcgRIIA is
dependent on aIIbb3
To further investigate the role of FcgRIIA in platelet activation by
bacteria, we monitored tyrosine phosphorylation. Because of the
high levels of plasma proteins, whichmask tyrosine phosphorylation
using standard extraction procedures,we used amethod that involves
removal of plasma proteins prior to cell lysis. We observed marked
increase in tyrosine phosphorylation of FcgRIIA and its downstream
signaling partners, Syk and PLCg2, in platelets that had undergone
aggregation in response to bacteria or to cross-linked mAb IV.3
(Figure 3A), whereasweak or negligible phosphorylation of FcgRIIA,
Syk, and PLCg2 was detected in lysates from TRAP-induced aggre-
gates (Figure 3A). Although FcgRIIA phosphorylation in response to
Figure 1. Bacteria stimulate platelet aggregation and secretion in plasma. (A)
Characterization of the lag time for onset of aggregation in response to bacteria.
Platelet aggregation in response to bacterial strains belonging to 5 different gram-
positive species was monitored in plasma by light transmission aggregometry. Final
concentrations of bacteria were S sanguinis 133-79, 0.6 3 108 CFU/mL; S aureus
Newman, 1 3 108 CFU/mL; S gordonii DL1, 3 3 108 CFU/mL; S oralis CR834,
4 3 108 CFU/mL; S pneumoniae IO1196, 0.7 3 108 CFU/mL. Results are shown as
mean 6 SD of 4 independent experiments. (B) Effect of aIIbb3 inhibitor Integrilin on
platelet dense granule secretion in response to bacteria. Aggregation reactions were
performed in plasma in the presence of Integrilin (9 mM) or vehicle; supernatants
collected at time of full aggregation, or a parallel time point in the case of inhibition.
Supernatants were analyzed for ATP release by luciferin-luciferase assay. ATP
levels released in 32 mM TRAP-stimulated platelets were used to normalize data.
Results are shown as mean 6 SD of 4 independent experiments; *P , .05. (C)
Effect of aIIbb3 inhibitor Integrilin on platelet PF4 release in response to bacteria.
Aggregation reactions were performed in plasma in the presence of Integrilin
(9 mM) or vehicle and supernatants collected at time of full aggregation, or
a parallel time point in the case of inhibition. Levels of soluble PF4 were
measured in duplicates by PF4 ELISA. Results are shown as mean 6 SD of 4
independent experiments; *P , .05.
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TRAP has been reported in washed platelets,27 and confirmed by us
(not shown), the present results show that FcgRIIA phosphorylation
by TRAP is almost undetectable when aggregation is performed in
plasma.
Time-course studies were conducted to monitor FcgRIIA phos-
phorylation. Tyrosine phosphorylation of the receptor was coin-
cident with the onset of platelet aggregation, with no detectable
increase prior to this time (not shown). Moreover, FcgRIIA phos-
phorylation induced by bacteria, but not in response to clustering of
mAb IV.3, was blocked in the presence of Integrilin (Figure 3B).
Thus, phosphorylation of FcgRIIA by bacteria, like secretion, is
dependent on aIIbb3 engagement.
Platelet activation by bacteria is also dependent on ADP
and TxA2
Platelet activation is reinforced by release of stored adenosine
59-diphosphate (ADP) from dense granules and de novo synthesis
of thromboxane A2 (TxA2). The P2Y12 antagonist, cangrelor, and
cyclooxygenase inhibitor, indomethacin, were used to investigate
a role for the 2 feedback agonists in bacteria-induced platelet
aggregation. Activation was inhibited to varying degrees in the
presence of 1 of the 2 inhibitors (Figure 4), but with complete
blockade observed in the presence of both inhibitors (Figure 4;
supplemental Figure 3). In contrast, response to cross-linked mAb
IV.3 was not affected, although deaggregation was observed at later
time points (supplemental Figure 3). Thus, platelet activation by
bacteria is also dependent on ADP and TxA2.
hIgGs reconstitute aggregation to bacteria in washed platelets
Washed platelets were used to investigate the requirement for plasma
components in supporting platelet activation by bacteria. None of the
5 strains induced aggregation in washed platelets, in contrast to the
robust response to TRAP and cross-linked mAb IV.3 (not shown).
Due to the critical role for FcgRIIA andaIIbb3 in supporting platelet
activation in plasma, we considered whether the absence of IgG and/
or fibrinogen could account for this result. In line with this, full
aggregation to bacteria in washed platelets was restored in the
presence of hIgG (Figure 5). The lag time for aggregation to S aureus
Newman, S gordoniiDL1, and S oralisCR834 but not to S sanguinis
133-79 was reduced when IgG was added together with fibrinogen,
Figure 2. FcgRIIA and Src and Syk tyrosine kinases mediate bacteria-induced platelet activation. (A) Effect of anti-FcgRIIA mAb IV.3 on bacteria-induced platelet
aggregation. PRP was incubated for 10 minutes with mAb IV.3 (10 mg/mL) or vehicle prior to addition of bacteria or protease-activated receptor 1 agonist TRAP, and platelet
aggregation was monitored by light transmission aggregometry (see also supplemental Figure 2B). (B) Effect of anti-FcgRIIA mAb IV.3 on platelet dense granule secretion in
response to bacteria. Reactions were performed as in panel A; supernatants were collected at time of full aggregation, or a parallel time point in the case of inhibition.
Supernatants were analyzed for ATP release by luciferin-luciferase assay. ATP levels released by S sanguinis 133-79–stimulated platelets were used to normalize data. (C)
Effect of the Src tyrosine kinase inhibitor dasatinib in bacteria-induced platelet aggregation in plasma. PRP was incubated for 2 minutes with dasatinib (4 mM) prior to addition
of bacteria or agonists, and platelet aggregation was monitored (see also supplemental Figure 2C). (D) Effect of Syk tyrosine kinase inhibitor PRT-060318 in bacteria-induced
platelet aggregation in plasma. PRP was incubated for 2 minutes with PRT-060318 (10 mM) or vehicle prior to addition of bacteria or agonist, and platelet aggregation was
monitored (see also supplemental Figure 2D). Results are shown as mean 6 SD of 3 independent experiments; *P , .05.
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although on its own, fibrinogen alone was unable to restore aggre-
gation to the 4 strains (Figure 5). For S aureus Newman, IgG-
depleted fibrinogen was used, as the presence of residual IgGs is
sufficient to support aggregation to this strain (Fitzgerald et al40 and
not shown). We were unable to consistently restore aggregation
to S pneumoniae IO1196 in the presence of IgG and fibrinogen
(aggregationwas observed in 2 of 5 donors after times.15minutes),
suggesting that other plasma components might be required for
robust activation. These results demonstrate that IgG and fibrinogen
are required to support bacteria-induced aggregation in washed
platelets.
Only S aureus Newman induces aggregation of
FcgRIIA-transgenic mouse platelets
The FcgRIIA receptor is absent in the mouse genome, and mouse
platelets do not express an Fc receptor.41 None of the bacterial strains
induced aggregation of wild-type mouse platelets in plasma, even in
the presence of hIgG (not shown). And, interestingly, only S aureus
Newman stimulated platelet aggregation from transgenic mice that
expressFcgRIIA (Figure 6A, andnot shown).Aggregation toSaureus
Newman in the transgenic platelets (including endogenousfibrinogen)
was strictly dependent on hIgG and was blocked in the presence of
the mouse aIIbb3 antagonist lotrafiban and the Src kinase inhibitor
dasatinib (Figure 6B).
PF4 modulates bacteria-induced platelet aggregation
The platelet a-granule–secreted chemokine PF4 has recently been
proposed to have a critical role in the innate defense system by
coating bacteria and binding to circulating IgGs, thereby targeting
bacteria for phagocytosis.25 To test whether PF4 could also have an
effect on bacteria-induced platelet activation, we first measured
binding of PF4 to the 5 strains in both buffer and plasma. Marked
bindingwas observed to all strains in buffer (Figure 7Ai)with amuch
lower level of binding in plasma (Figure 7Aii), most likely due to
binding of PF4 to plasma proteins. Indeed, in the case of S aureus
Newman, the binding of PF4 in plasma was undetectable.
We then monitored the effect of PF4 on the lag time to activation.
Addition of PF4 (20 mg/mL) to washed platelets in the presence of
IgG and fibrinogen reduced the time to onset of aggregation for the
5 strains (Figure 7B), although PF4 alone had no effect on its own
(not shown).
PF4 (3-100 mg/mL) had no significant effect on bacteria-induced
platelet activation in plasma (not shown), which againmay reflect the
high level of binding to plasma proteins. This observation does not
exclude a possible role in supporting bacterial activation of platelets,
when a high local PF4 concentration might induce significant
binding to bacteria. To investigate this, we used heparin, which binds
with high affinity to PF442 and forms multimolecular PF4/heparin
complexes that at optimal molar ratios promote PF4 adhesion to
platelets43 and bacteria (K.K. andA.G., unpublished observation), as
well as platelet activationbyHITantibodies.24,43,44At concentrations up
Figure 3. Bacteria induce tyrosine phosphorylation
of FcgRIIA that is dependent on aIIbb3 activation.
(A) Tyr phosphorylation of FcgRIIA and downstream
mediators during bacteria-induced platelet aggregation
in plasma. Cell lysates were collected at time of full
aggregation; IPs were performed for FcgRIIA, Syk, and
PLCg2. As previously described,37 FcgRIIA coprecipi-
tated during Syk IP and, therefore, phosphorylated Syk
and FcgRIIA were detected in the same gel. (B) Effect
of aIIbb3 inhibitor Integrilin on FcgRIIA phosphorylation
during bacteria-induced platelet activation. Aggregation
reactions were performed in plasma in the presence or
absence of Integrilin (9 mM); cell lysates were collected
at time of full aggregation, or equivalent times in the
case of Integrilin-treated samples where aggregation
was inhibited. IPs for FcgRIIA were performed; tyrosine
phosphorylation was detected by western blot. Repre-
sentative results of 3 independent experiments are
shown.
Figure 4. Secondary mediators TxA2 and ADP are key for bacteria-induced
platelet aggregation. PRP was incubated for 2 minutes with COX inhibitor
indomethacin (10 mM), ADP-receptor P2Y12 inhibitor cangrelor (1 mM), or vehicle
(DMSO) prior to addition of bacteria or cross-linked mAb IV.3, and platelet
aggregation was monitored. Results are shown as mean 6 SD of 3 independent
experiments; *P , .05 (see also supplemental Figure 3). DMSO, dimethylsulfoxide.
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to 60 mg/mL, heparin reduced the lag time of aggregation to all 5
strains of bacteria in plasma, whereas at higher concentrations the
effect was strain-specific, ranging from a reduction or increase in lag
time, or abolition of response (Figure 7C; supplemental Figure 4A).
Heparin had no effect on platelet aggregation either on its own or on
TRAP-induced aggregation at any of the concentrations used in this
study (supplemental Figure 4B-C). The dose-dependency of the
effect of heparin on platelet activation is similar to that seen in HIT
serum, with low concentrations inducing activation and higher
concentrations causing abolition of response.
a-granule–deficient platelets do not respond to most bacteria
We used platelets from a patient with GPS, who lacks platelet
a-granules, to further investigate a possible role for PF4 in platelet
activation to bacteria. Because GPS is associated with a mild
thrombocytopenia, these studies were performed with a lower
platelet count of 1 3 108/mL, alongside a control with diluted
plasma. Whereas all strains induced robust aggregation in the
control, only S oralisCR834 induced aggregation of GPS platelets
and this was blocked by mAb IV.3, confirming its dependency on
FcgRIIA (Figure 7D). These data support a role for a-granule
secretion in supporting platelet activation to 4 of the 5 strains.
Discussion
The 5 gram-positive bacterial strains included in this study belong to
different species and are known to interact with platelets using strain-
specific interactions as outlined in the Introduction. We have per-
formed a systematic comparison of the 5 bacteria and found that they
also share a common pathway of platelet activation that involves
FcgRIIA activation of Src and Syk kinases and that this is reinforced
byaIIbb3engagement andgranule secretion (supplemental Figure5).
This puts previous observations of a potential role for FcgRIIA in
platelet activation13,15,16,38,39 into a new context: FcgRIIA is likely
a central pathway involved in bacteria host interaction in humans.
Furthermore, this is the first study demonstrating that FcgRIIA- and
aIIbb3-dependent a- and dense granule secretion is important for
bacteria-induced platelet aggregation.
Regulation of FcgRIIA phosphorylation by bacteria is distinct
from that mediated by direct cross-linking of the receptor. Cross-
linking of the anti-FcgRIIAmAb IV.3 induces powerful aggregation
and secretion with no discernible delay in response. Activation is
associated with marked phosphorylation of FcgRIIA and is
independent ofaIIbb3 engagement. In contrast, platelet aggregation
induced by our 5 bacteria is associatedwith a lag phase, and FcgRIIA
phosphorylation is dependent onaIIbb3 engagement. This is similar
to S sanguinis strain 2017-78, in which aIIbb3 engagement is
required for sustained FcgRIIA phosphorylation.45 Moreover,
bacteria-induced aggregation requires release of ADP and TxA2,
and, for 4 of the 5 strains, a-granule secretion. The involvement of
these feedback pathways accounts for the “all-or-nothing” nature
of platelet activation by bacteria, with FcgRIIA playing a critical
role in both the initiation of activation and the feedback response. In
this respect, bacteria-induced aggregation is different from that
mediated by typical platelet agonists like TRAP. FcgRIIA can
function as a membrane adaptor that amplifies the activation of
Src/Syk kinases by integrin aIIbb3 independent of IgG.27,28 How-
ever, this mechanism alone cannot account for the level of phos-
phorylation of FcgRIIA observed in response to bacteria, as
aggregation caused by TRAP induces a much lower level of FcgRIIA
Figure 5. hIgGs reconstitute aggregation to bacteria in washed platelets. Aggregation reactions to S sanguinis 133-79, S aureus Newman, S gordonii DL1, and S oralis
CR834 were performed in washed platelets in the presence or absence of fibrinogen (1 mg/mL) and hIgGs (0.1 mg/mL). For S aureus Newman, IgG-depleted fibrinogen was
used as previously published.40 One representative reaction of 3 independent experiments per strain is shown.
Figure 6. S aureus Newman induces aggregation of
FcgRIIA-transgenic mouse platelets. (A) Comparison
of FcgRIIA-transgenic vs wild-type mouse platelets in
response to S aureus Newman. Aggregation reactions
were performed in mouse PRP. Platelets were stimu-
lated with S aureus Newman plus hIgGs (0.5 mg/mL),
with S aureus Newman alone or with hIgG alone. One
representative experiment of 3 is shown. (B) Effect of
aIIbb3 inhibitor lotrafiban and Src inhibitor dasatinib on
S aureus Newman-induced aggregation of FcgRIIA-
transgenic platelets. Aggregation reactions were per-
formed as in panel A in the presence of 0.5 mg/mL hIgG
after platelet preincubation with lotrafiban (10 mM),
dasatinib (20 mM), or vehicle (DMSO). Results are
shown as mean 6 SD of 3 independent experiments;
*P , .05.
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phosphorylation in plasma. Thus, aIIbb3 engagement per se does not
lead to robust FcgRIIA phosphorylation.
We propose that, after binding of bacteria to the platelet surface
through a variety of strain-specific pathways, the initiating event in
activation is engagement of FcgRIIAbyplasma IgGbound tobacteria,
as activation is reconstituted inwashedplatelets in the presence of IgG.
The inability to detect FcgRIIA tyrosine phosphorylation in the ab-
sence of aIIbb3 engagement reflects the weak nature of this pathway
of activation in the absence of feedback signals. In turn, FcgRIIA
reinforces activation through a pathway that is dependent on aIIbb3
engagement and granule secretion. The mechanism by which initial
activation ofaIIbb3 takes place is likely to be strain-specific. Formost
bacteria, inside-out activation of aIIbb3 might be achieved by
FcgRIIA signaling, as well as by signaling from other strain-specific
interactions. However, some bacteria such as S gordonii DL1 and
S aureus Newman have surface proteins that bind to aIIbb3, which
could facilitate aIIbb3 activation.4,18,46,47 Moreover, S aureus
Newman ClfA/B is known to bind to fibrinogen and hIgG si-
multaneously, which then leads to cross-linking of aIIbb3 and
FcgRIIA.4,46,47 In this way, ClfA/B might engage a strong co-
operation between these receptors. This could explain why this
strain induces aggregation of FcgRIIA-transgenic mouse plate-
lets, in which cooperation between the 2 receptors has been
reported.28 The absence of FcgRIIA-transgenic platelet aggrega-
tion to the other bacteria might be due to poor conservation of the
strain-specificmolecular interactions that are required to facilitate
subsequent FcgRIIA-mediated activation.
In all cases, FcgRIIA and aIIbb3 engagement results in a weak
signal leading to release of ADP, TxA2, and PF4. At this stage,
feedbackmechanisms are key in order to achieve full activation and
Figure 7. Bacteria-induced platelet aggregation is modulated by PF4 and heparin and is impaired in GPS platelets. (A) PF4 binding to bacteria. Bacteria were
incubated with 20 mg/mL biotinylated human PF4 in buffer (i) or in the presence of 46% plasma from healthy donors (ii). After a secondary incubation with peridinin chlorophyll
protein-Cy5.5–conjugated streptavidin, PF4 binding was analyzed by flow cytometry (Cytomics FC 500; Beckman Coulter). The GMFI multiplied by the percentage of labeled
bacteria constituted binding activity. Results shown are mean 6 SD of 3 independent experiments; *P , .05. (B) Effect of PF4 on the lag time for onset of bacteria-induced
platelet aggregation. Washed platelets were supplemented with fibrinogen (1 mg/mL) and hIgGs (0.1 mg/mL). Purified human PF4 (20 mg/mL) and bacteria were added
simultaneously to the platelet preparation and aggregation was recorded (S sanguinis 133-79, n 5 2; S aureus Newman, n 5 2; S gordonii DL1, n5 6; S oralis CR834, n 5 3;
S pneumoniae IO1196, n 5 2). (C) Effect of heparin on bacteria-induced platelet aggregation. Aggregation reactions were performed in plasma in the presence of varying
doses of UFH: 0.06 mg/mL (0.0125 U/mL), 0.6 mg/mL (0.125 U/mL), 6 mg/mL (1.25 U/mL), 60 mg/mL (12.5 U/mL), 600 mg/mL (125 U/mL), 3000 mg/mL (625 U/mL). UFH was
preincubated with platelets for 2 minutes before adding bacteria. Changes in lag time in UFH-treated reactions are presented as the mean 6 SEM; *P , .05 (S sanguinis
133-79, n 5 6; S aureus Newman, n 5 5; S gordonii DL1, n 5 6; S oralis CR834, n 5 5; S pneumoniae IO1196, n 5 6). For S sanguinis 133-79, S gordonii DL1, and
S pneumoniae IO1196, 3000 mg/mL UHF inhibited aggregation in all donors (not shown). Lag times (mean 6 SD) in the untreated reactions were: S sanguinis 133-79,
273 6 180 seconds; S aureus Newman, 218 6 101 seconds; S gordonii DL1, 528 6 136 seconds; S oralis CR834, 206 6 82 seconds; S pneumoniae IO1196, 410 6 152
seconds (see also supplemental Figure 4). (D) Bacteria-induced platelet aggregation in GPS and control platelets. The final platelet concentration in GPS PRP was 1 3 108
platelets per mL and, therefore, the control PRP was diluted in buffer to obtain the same concentration. ADP (30mM) was used as a control agonist for platelet aggregation.
Two duplicates were performed per each reaction and sample, and 1 representative trace is shown. Lag times for the reactions shown are: S sanguinis 133-79, 2 minutes;
S aureus Newman, 7 minutes 10 seconds; S gordonii DL1, 20 minutes; S oralis CR834, 6 minutes (GPS platelets, 4 minutes); S pneumoniae IO1196, 8 minutes. GMFI,
geometric mean fluorescence intensity.
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aggregation. In 4 of 5 strains, activation is reinforced by a pathway
that depends on a-granule secretion as shown by the lack of aggre-
gation in GPS platelets. Based on literature on leukocyte recog-
nition of antibodies against PF4/bacteria complexes,25,26 we propose
that PF4/bacteria complexes could also contribute to platelet activa-
tion. Indeed, the addition of PF4 reduced the lag time of aggregation,
although only in a plasma-free system supplemented with fibrinogen
and IgG. The absence of a similar observation in plasma may reflect
the high level of binding of PF4 to plasma proteins. However, indirect
evidence in support of this is the demonstration in plasma that heparin
reduces the lag time to activation whereas at higher concentrations
this effect is lost or reversed, in a similar way to its effect on platelet
activation by HIT antibodies.24,43,44 Consistently, it has been
described that platelet activation assays for HIT diagnosis using
washed platelets are more sensitive than assays using PRP.48
There are several potential mechanisms through which PF4 could
reinforce bacteria-induced platelet activation such as reinforce-
ment of FcgRIIA signaling by bacteria-bound PF4/IgG com-
plexes, synergy with direct interaction of PF4 with platelet
receptors, or charge interactions promoting bacteria-platelet cell
contact. In this context, ADP/TxA2 might still contribute to acti-
vation by reinforcing inside-out aIIbb3 activation and a-granule
secretion leading to a strong positive feedback cascade. For S oralis,
a-granule secretion is not mandatory for aggregation, which suggests
that it is using ADP/TxA2 very efficiently to feedback on aIIbb3 and
FcgRIIA activation without requirement for PF4. The ways in which
bacteria use FcgRIIA to mediate activation are summarized in
supplemental Figure 5.
For all strains, aggregation depends on ADP/TxA2 mediating
aIIbb3 inside-out activation in the neighboring (bacteria-free)
platelets. Therefore, the release of secondary mediators starts a
process in which aIIbb3 activation and release of ADP/TxA2 feed-
back on each other. During aggregation, FcgRIIA signaling is likely
being reinforced as a consequence of aIIbb3 engagement and con-
tributes to a cooperative integrin/immunoreceptor tyrosine-based
activation motif signaling.27,28
In summary, in this study we provide evidence that bacteria
induce activation of platelets through strain-specific interactions
and a common pathway that involves FcgRIIA and aIIbb3 en-
gagement and granule secretion. The demonstration of a common
mode of activation identifies FcgRIIA as a candidate receptor for
prevention of bacterial-mediated platelet activation in thrombotic-
related disorders.
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